Business
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July 29, 2024 (GLOBE
About this update from Inmune Bio Inc.
[{"type":"text","content":"AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease is pleased to be presenting results of a new and advanced proteomic analysis at this year’s annual Alzheimer’s Association International Conference (AAIC) in Philadelphia, PA. The poster summarizes dose-related changes in the cerebrospinal fluid (CSF) proteome in patients with Alzheimer’s disease (AD) treated with XProTM in the company’s phase 1b study. Monday, July 29Poster #95343Dose-related modulation of the synaptic proteome after short-term treatment with XPro1595 for Alzheimer's disease The new analysis revealed that a 12-week treatment with XPro™ resulted in a significant change in synaptic proteins, which are essential for communication between neurons. “The loss of synapses begins early in Alzheimer’s disease and has devastating consequences as the disease progresses,” stated CJ Barnum, PhD, VP of Neuroscience at INmune Bio. “The robust effect of XProTM on a broad number of proteins and pathways that regulate the formation of synapses is consistent with what we have observed in preclinical models and what we expect to happen when normal/healthy immune function is restored.” The formation and elimination of synapses is executed by cells of the innate immune system such as astrocytes. When these cells are in a dysregulated inflammatory/immune state, synapse formation is reduced and synapse elimination is increased, resulting in loss of communication between neurons which, in the case of AD, results in cognitive impairment. Restoring synapses requires a normally functioning innate immune system. “We are encouraged by this new evidence of a treatment effect at the cellular level in proteins known to be affected by AD pathologies,” said Company CEO RJ Tesi, MD. “XPro’s direct impact on synaptic proteins provides further support to the improvement in synaptic function we recently observed with EEG data and provides further evidence that we are having a significant effect on restoring the immune system. This is yet another biological precursor to what we believe will r...